Company intelligence / Profile preview

BeaMed Technologies

Israel

Ownership: Private
Development stage: Other

Overview

BeaMed is developing the StingRay laser-based thermal ablation system for minimally invasive treatment of drug‑resistant epilepsy and solid tumors; as of mid‑2023 the company reported successful manufacturing of first MRI‑compatible fiber optic probes and preparation for integration testing, but no human clinical trial results have been publicly reported yet.[2][3][4]

Therapeutic areas: OncologyNeurology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Innovation Pharmaceuticals (minority stakeholder and lead investor)[3][4]BIRD Foundation (Israel–US binational R&D grant supporter)[3][4]

Beyond the preview

Go deeper on BeaMed Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BeaMed Technologies.

Explore the full profile